Form 4: Pyxis Oncology Director Freda Lewis-Hall Reports Acquisition of Restricted Stock Units

Director Freda Lewis-Hall reports acquisition of 35,219 restricted stock units in Pyxis Oncology, Inc.

Summary

• On March 26, 2024, Freda Lewis-Hall, a director of Pyxis Oncology, Inc. [PYXS], acquired 35,219 shares of Common Stock.
• These shares were acquired as restricted stock units.
• Following the transaction, Lewis-Hall beneficially owns 241,405 shares of Pyxis Oncology.
• The restricted stock units vest 100% on the first anniversary of the grant date, contingent upon continued service.

Sentiment

Score: 6

Explanation: The sentiment is neutral. It's a standard disclosure of stock units granted to a director, which is neither particularly positive nor negative.

Positives

• The acquisition of restricted stock units by a director signals confidence in the company's future.

Future Outlook

The restricted stock units vest 100% on the first anniversary of the grant date, subject to continued service.

Industry Context

This filing is a routine disclosure of insider transactions, which are common in publicly traded companies. Investors often monitor these filings for signals about management's confidence in the company's prospects.

Stakeholder Impact

• The transaction could have a minor positive impact on shareholder sentiment, as it indicates a director's continued alignment with the company's success.

Key Dates